Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
AssigneeInnogenetics N.V.
InventorRobert De Leys
Life of this patent
Estimating the term…
Abstract
The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention relates to a process for the in vitro determination of antibodies, wherein the peptides used are biotinylated, particularly in the form of complexes of streptavidin-biotinylated peptides or of avidin-biotinylated peptides.
Claims52
A peptide consisting of an amino acid sequence of SEQ ID NO 454
- (A)-GHTRVSGGAAASDTRGLVSLFSPGSAQKIQLVNT-(Z) (SEQ ID NO 454), wherein A, when present, represents an amino acid, amino group, or chemically modified amino terminus of the peptide, and wherein Z, when present, represents an amino acid, OH-group, NH2-group, or a linkage involving an OH-group or an NH2-group
- or a peptide fragment consisting of at least 5 amino acids of SEQ ID NO:
- 454 which is immunologically reactive with HCV antisera.
A peptide consisting of an amino acid sequence of SEQ ID NO:
- 454
- (A)-GHTRVSGGAAASDTRGLVSLFSPGSAQKIQLVNT-(Z) (SEQ ID NO 454), wherein A, when present, represents an amino acid, amino group, or chemically modified amino terminus of the peptide, and wherein Z, when present, represents an amino acid, OH-group, NH2-group, or a linkage involving an OH-group or an NH2-group;
- or a peptide fragment consisting of at least 5 amino acids of SEQ ID NO:
- 454 which is immunologically reactive with HCV antisera;
- and
- said peptide or peptide fragment containing at least one N-terminal biotin group, C-terminal biotin group or biotin group attached to an internal amino acid;
- said biotin group being attached directly to the peptide or peptide fragment or attached to the peptide or peptide fragment through a linker Y;
- said linker Y consisting of 1 to 10 chemical entities selected from the group consisting of a glycine residue, beta-alanine, 4-aminobutyric acid, 5-aminovaleric acid and 6-aminohexanoic acid.
A peptide consisting of an amino acid sequence of SEQ ID NO 454
- (A)-THTRVSGGAAASDTRGLVSLFSPGSAQKIQLVNT-(Z) (SEQ ID NO 454), wherein A, when present, represents an amino acid, amino group, or chemically modified amino terminus of the peptide, and wherein Z, when present, represents an amino acid, OH-group, NH2-group, or a linkage involving an OH-group or an NH2-group;
- or a peptide fragment consisting of at least 5 amino acids of SEQ ID NO:
- 454.
A peptide consisting of an amino acid sequence of SEQ ID NO 454
- (A)-GHTRVSGGAAASDTRGLVSLFSPGSAQKIQLVNT-(Z) (SEQ ID NO 454), wherein A, when present, represents an amino acid, amino group, or chemically modified amino terminus of the peptide, and wherein Z, when present, represents an amino acid, OH-group, NH2-group, or a linkage involving an OH-group or an NH2-group;
- or a peptide fragment consisting of at least 5 amino acids of SEQ ID NO:
- 454;
- and
- said peptide or peptide fragment containing at least one N-terminal biotin group, C-terminal biotin group or biotin group attached to an internal amino acid;
- said biotin group being attached directly to the peptide or peptide fragment or attached to the peptide or peptide fragment through a linker Y;
- said linker Y consisting of 1 to 10 chemical entities selected from the group consisting of a glycine residue, beta-alanine, 4-aminobutyric acid, 5-aminovaleric acid and 6-aminohexanoic acid.
Dependencies are inferred from the claim text.